This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Lumateperone for acute exacerbations of psychosis in schizophrenia

< Back

Lumateperone for acute exacerbations of psychosis in schizophrenia


Mental Health, Drug Abuse and Learning Difficulties

May 2017

Lumateperone is a new, orally administered antipsychotic drug which alters levels of several chemicals in the brain including dopamine, serotonin and glutamate. Studies on lumateperone in people with schizophrenia experiencing an episode of severe symptoms suggest it may reduce symptoms with less side effects than current antipsychotic medication.If licensed lumateperone may provide an alternative treatment option for people with schizophrenia which may cause fewer side effects.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts